Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Schedule A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LX4211 | EXPERIMENTAL | 400 mg of LX4211 administered orally |
| Placebo | PLACEBO_COMPARATOR | Nonidentical placebo administered orally |
| Name | Type | Description |
|---|---|---|
| Schedule A | DRUG | Dosing 1 hour before breakfast |
| Schedule B | DRUG | Dosing 0.5 hour before breakfast |
| Schedule C | DRUG | Dosing immediately before breakfast |
| Schedule D | DRUG | Dosing immediately before lunch |
| Schedule E | DRUG | Split dose, dosing 1 hour before breakfast and dinner |
Inclusion Criteria: * Adults ≥18 and ≤55 years of age * Vital signs at Screening in the following ranges: systolic blood pressure, 90-140 mm Hg; diastolic blood pressure, 50-90 mm Hg; heart rate, 50-100 bpm * Body mass index (BMI) ≥18 and ≤35 kg/sq m * Able to provide written informed consent Excl...
Schedule A is an investigational small molecule being developed by Lexicon Pharmaceuticals, Inc. (LXRX). It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers, and its therapeutic area is classified as Other. It is not approved and remains in clinical testing.
Schedule A is being studied for use in healthy subjects. The completed Phase 1 trial evaluated the pharmacodynamics of the drug relative to meals in healthy volunteers. No specific disease indication has been established for Schedule A at this time.
Schedule A is being developed by Lexicon Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol LXRX. The company is conducting clinical research on this investigational small molecule drug.
Schedule A is in Phase 1 clinical development. One Phase 1 trial has been completed, and there are no active trials currently listed. The drug is investigational and has not been approved by regulatory authorities.
Schedule A has one completed clinical trial registered as NCT01334242, titled 'A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects.' This Phase 1 study enrolled 14 participants in the United States and was placebo-controlled, randomized, and double-blind.
Yes, Schedule A is also known as LX4211. The clinical trial NCT01334242 refers to the drug as LX4211, indicating that Schedule A and LX4211 are the same investigational compound being developed by Lexicon Pharmaceuticals.